EF Hutton：重申Pasithea Therapeutics(KTTA.US)评级，由买入调整至买入评级, 目标价2.00美元。
EF Hutton：重申Pasithea Therapeutics(KTTA.US)评级，由买入调整至买入评级, 目标价2.00美元。
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.